Shenzhen Hepalink Pharmaceutical Group Co Sustainability Profile
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., commonly known as Hepalink, is a leading global player in the pharmaceutical industry, headquartered in Shenzhen, China. Founded in 1998, the company has established itself as a prominent manufacturer and supplier of heparin and its derivatives, catering to both domestic and international markets. Hepalink's core offerings include active pharmaceutical ingredients (APIs) and finished dosage forms, with a strong emphasis on anticoagulant therapies. The company is renowned for its commitment to quality and innovation, which has positioned it as a trusted partner in the healthcare sector. With a robust presence in Europe, North America, and Asia, Hepalink continues to achieve significant milestones, including regulatory approvals and strategic partnerships, solidifying its reputation as a leader in the biopharmaceutical landscape.
DitchCarbon Score
How does Shenzhen Hepalink Pharmaceutical Group Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shenzhen Hepalink Pharmaceutical Group Co's score of 32 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shenzhen Hepalink Pharmaceutical Group Co's reported carbon emissions
In 2024, Shenzhen Hepalink Pharmaceutical Group Co., based in China, reported total carbon emissions of approximately 18,284,000 kg CO2e for Scope 1 and about 33,329,700 kg CO2e for Scope 2, resulting in a combined total of around 51,613,700 kg CO2e. This marks a decrease from 2023, where emissions were approximately 24,672,900 kg CO2e for Scope 1 and 31,201,200 kg CO2e for Scope 2, totalling about 55,874,200 kg CO2e. In 2022, the company recorded emissions of about 24,355,200 kg CO2e for Scope 1 and 33,994,200 kg CO2e for Scope 2, leading to a total of approximately 58,349,400 kg CO2e. The trend shows a reduction in emissions over the years, with 2021 figures at approximately 25,352,500 kg CO2e for Scope 1 and 40,527,100 kg CO2e for Scope 2, totalling around 65,879,600 kg CO2e. Despite these reductions, Shenzhen Hepalink has not set specific reduction targets or initiatives, nor does it report any Scope 3 emissions. The company has not disclosed any climate pledges or commitments to further reduce its carbon footprint. All emissions data is sourced directly from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. without any cascading from a parent or related organization.
How Carbon Intensive is Shenzhen Hepalink Pharmaceutical Group Co's Industry?
How Carbon Intensive is Shenzhen Hepalink Pharmaceutical Group Co's Location?
Shenzhen Hepalink Pharmaceutical Group Co's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shenzhen Hepalink Pharmaceutical Group Co has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.